Hikma signs licensing deal with Faes Farma

17th Jul 2009 07:17

Hikma Pharmaceuticals has signed a licensing agreement for the anti-histamine Bilastine with Spain's Faes Farma for the Middle East & North Africa (MENA) region. Through this agreement Faes Farma grants exclusive rights for the manufacture and distribution of Bilastine to Hikma for 17 MENA countries, while reserving its co-marketing rights in some of them. "This agreement reinforces our position as the partner of choice for marketing branded products in the MENA region. In-licensing is a key part of our growth strategy in the region and accounts for more than 30% of sales in our Branded business," said chief executive Said Darwazah."We are pleased to have secured the license for this important anti-histamine and look forward to making Bilastine available to our customers across the MENA region."